PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 171 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.41 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,232,051 | +22.0% | 133,816 | +102.0% | 0.01% | 0.0% |
| Q2 2023 | $1,830,129 | -40.0% | 66,261 | -50.1% | 0.01% | -87.0% |
| Q1 2023 | $3,051,410 | -46.7% | 132,670 | -74.7% | 0.05% | -55.8% |
| Q4 2022 | $5,720,135 | +559.0% | 524,302 | +409.3% | 0.10% | +511.8% |
| Q3 2022 | $868,000 | -57.4% | 102,943 | -60.0% | 0.02% | -69.6% |
| Q2 2022 | $2,036,000 | +157.4% | 257,357 | +670.8% | 0.06% | +166.7% |
| Q1 2022 | $791,000 | -76.4% | 33,390 | -65.9% | 0.02% | -79.8% |
| Q4 2021 | $3,352,000 | +1772.6% | 97,998 | +868.7% | 0.10% | +1980.0% |
| Q3 2021 | $179,000 | – | 10,116 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $20,647,000 | 6.08% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $19,057,000 | 2.28% |
| Kynam Capital Management, LP | 519,212 | $4,377,000 | 0.92% |
| RTW INVESTMENTS, LP | 4,176,837 | $35,211,000 | 0.81% |
| Tri Locum Partners LP | 199,500 | $1,682,000 | 0.46% |
| Birchview Capital, LP | 38,000 | $320,000 | 0.22% |
| Gratus Capital, LLC | 206,113 | $1,738,000 | 0.18% |
| FARALLON CAPITAL MANAGEMENT LLC | 3,651,887 | $30,785,000 | 0.17% |
| PDT Partners, LLC | 126,038 | $1,063,000 | 0.16% |
| FOX RUN MANAGEMENT, L.L.C. | 40,683 | $343,000 | 0.13% |